InsiderSource

LOBELL J JAY

Director, CEO and Secretary · SEC CIK 1172659
Insider at FBIO Fortress Biotech, Inc. PRDS PARDES BIOSCIENCES, INC. CNDO CORONADO BIOSCIENCES INC [CNDO] CORONADO BIOSCIENCES INC CORONADO BIOSCIENCES INC CHRX.OB CHEM RX CORP NVD NOVADEL PHARMA INC IVPH.OB CytRx Oncology Corp PMQC.OB CHEM RX CORP NORTON SOUND ACQUISITION CORP. SITKA SCIENCES, INC. PMQC Paramount Acquisition Corp
Advertisement

Buy track record

How this insider's open-market purchases have performed
0%
of buys now in profit
0 up · 1 down
Avg return since buy−73.1%
Median return−73.1%
Best trade−73.1%
Worst trade−73.1%
Buys scored1 (+3 n/a)
Average return by holding period — separates good entry timing from riding one long winner
After 1 month −5.3% 0% won · 1 trade
After 3 months −2.6% 0% won · 1 trade
After 6 months −30.3% 0% won · 1 trade
After 12 months −83.2% 0% won · 1 trade
DateCompany90d trendBuy priceValueΔOwn1M3M6M12MTo date
Feb 10, 2023 FBIO $1 $250K +22% −5.3% −2.6% −30.3% −83.2% −73.1%
How this is calculated. We score only open-market purchases (SEC code P) — the buys that carry real signal. Each trade's return is measured from the adjusted closing price on the purchase date to the latest close, accounting for stock splits and dividends. The 1M/3M/6M/12M columns show the same trade's return after each fixed holding period; a dash means that horizon hasn't elapsed yet or isn't priceable. Sales are excluded because insiders sell for many routine reasons. With only 1 scored trade, treat this as a small sample, not a verdict.
Advertisement
Open-market buys
$488.1K
4 trades
Open-market sells
$0
0 trades
Net flow
+$488.1K
Net buying
Total filings
25
transactions shown

Full transaction history

All Form 4 activity across every company, newest first
View on SEC EDGAR ↗
FBIO
Fortress Biotech, Inc.
Buy LOBELL J JAY · Director · Open-market purchase · filed Feb 14, 2023 ΔOwn +22%

Lobell J Jay, FBIO's Director, spent $250K of their own money on 299,401 shares at $1, growing their stake 22%.

+$250K
299,401 sh @ $1
Advertisement
CNDO
CORONADO BIOSCIENCES INC
Buy LOBELL J JAY · Director · Open-market purchase · filed Aug 22, 2013 ΔOwn +1.5%

Lobell J Jay, CNDO's Director, spent $36.9K of their own money on 5,000 shares at $7, growing their stake 2%.

+$36.9K
5,000 sh @ $7
CNDO
CORONADO BIOSCIENCES INC
Buy LOBELL J JAY · Director · Open-market purchase · filed Jun 21, 2013 ΔOwn +3.1%

Lobell J Jay, CNDO's Director, spent $76.2K of their own money on 10,000 shares at $8, growing their stake 3%.

+$76.2K
10,000 sh @ $8
CNDO
CORONADO BIOSCIENCES INC
Buy LOBELL J JAY · Director · Open-market purchase · filed Jun 26, 2012 ΔOwn +8.4%

Lobell J Jay, CNDO's Director, spent $125K of their own money on 25,000 shares at $5, growing their stake 8%.

+$125K
25,000 sh @ $5
CHRX.OB
CHEM RX CORP
Grant/award LOBELL J JAY · Director · Grant/award · filed Jan 21, 2009 ΔOwn +3.4%
+$0
10,964 sh
CHRX.OB
CHEM RX CORP
Grant/award LOBELL J JAY · Director · Grant/award · filed Oct 20, 2008 ΔOwn +0.3%
+$0
1,016 sh
PMQC.OB
CHEM RX CORP
Grant/award LOBELL J JAY · Director · Grant/award · filed Jan 28, 2008 ΔOwn +1.5%
+$0
4,717 sh

Frequently asked questions

How is LOBELL J JAY's win rate calculated?

We take every open-market purchase (SEC code P) we can match to a stock price, then compare the split- and dividend-adjusted price on the purchase date to the most recent close. The win rate is the share of those buys currently trading above the purchase price. Sales and share grants are not scored.

Why are some buys not included in the score?

A purchase is excluded if we can't price it — for example if the ticker is missing from the filing, the company has been delisted, or the security isn't a common stock we can match to market data. Excluded counts are shown next to the scored total.

What do the 1M / 3M / 6M / 12M columns mean?

They show each purchase's return after a fixed holding period — one, three, six, and twelve months from the buy date — using split- and dividend-adjusted prices. This separates good entry timing from simply holding a long-running winner. A dash means that horizon hasn't elapsed yet for that trade, or the stock couldn't be priced at that date.

Does a high win rate mean I should copy this insider?

No. Past performance does not predict future results, sample sizes are often small, and an insider's edge in their own company doesn't transfer to yours. This is context, not a recommendation. InsiderSource is not investment advice.

Where does this data come from?

Trades come from LOBELL J JAY's SEC Form 4 filings on EDGAR. Prices come from public market data and are split/dividend-adjusted. Always verify against the original filings before acting.